ASCO: Selpercatinib Improves Event-Free Survival in RET Fusion-Positive NSCLC

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on June 2, 2026.

via HealthDay

TUESDAY, June 2, 2026 -- For patients with RET fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC), the rearranged during transfection (RET) inhibitor, selpercatinib, yields significantly longer event-free survival, according to a study published online May 31 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 29 to June 2 in Chicago.

Yi‑Long Wu, M.D., from the Guangdong Lung Cancer Institute in Guangzhou, China, and colleagues conducted a phase 3, double-blind trial involving patients with RET fusion-positive NSCLC who had received definitive therapy with curative intent. Patients were randomly assigned to receive adjuvant selpercatinib or placebo for up to three years (75 and 76 patients, respectively).

The researchers found that the two-year investigator-assessed event-free survival was 92 and 61 percent with selpercatinib and placebo, respectively, among 109 patients with stage II or IIIA disease (hazard ratio for disease recurrence, progression, or death, 0.17). Investigator-assessed event-free survival was consistent with event-free survival as assessed by blinded independent central review. Investigator-assessed event-free survival at two years was 94 and 70 percent with selpercatinib and placebo, respectively, among the 151 patients with stage IB, II, or IIIA NSCLC (hazard ratio for disease recurrence, progression, or death, 0.17). Increased levels of alanine aminotransferase and aspartate aminotransferase were the most common adverse events observed during the treatment period. There were three deaths due to disease progression, all in the placebo group.

"These compelling results establish a new standard of care for a rare subset of lung cancer and are immediately practice-changing," David R. Spigel, M.D., the president and chief medical officer at Sarah Cannon Research Institute in Nashville, Tennessee, and an ASCO expert in lung cancer, said in a statement.

Several authors disclosed ties to biopharmaceutical companies, including Eli Lilly, which manufactures selpercatinib and funded the study.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-06-03 03:42

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords